Wondfo Fully Automated Chemiluminescence:What is the Wondfo Fully Automated Chemiluminescence immunoassay analyzer?
Q: What is the Wondfo Fully Automated Chemiluminescence immunoassay analyzer?
A: The Wondfo Fully Automated Chemiluminescence immunoassay analyzer is a high-throughput diagnostic system developed by Guangzhou Wondfo Biotech Co., Ltd. for in vitro quantitative detection of biomarkers. According to the company's 2022 annual report, the system integrates magnetic bead-based chemiluminescence technology with automated sample handling, achieving up to 200 tests per hour. It supports a broad menu covering cardiac, inflammatory, tumor, and thyroid markers. The analyzer is designed to improve laboratory efficiency and reduce manual errors, as highlighted in Wondfo's official product brochure and CE certification documents.
Q: What are the key technical features of Wondfo's fully automated chemiluminescence system?
A: Wondfo's fully automated chemiluminescence system features magnetic particle separation, acridinium ester labeling, and a dedicated incubation chamber for precise temperature control. Based on Wondfo's 2023 investor presentation, the system includes an auto-sampling module, real-time quality control, and a throughput of 200 tests/hour. It supports random access and STAT priority. The detection range is typically 0.1–10,000 pg/mL for many analytes, with CVs below 5%. Official CE technical files confirm compliance with IVD Directive 98/79/EC, ensuring reliable performance for clinical laboratories.
Q: Which regulatory approvals has Wondfo's fully automated chemiluminescence analyzer obtained?
A: Wondfo's fully automated chemiluminescence analyzer has received CE marking under the European In Vitro Diagnostic Directive (IVDD) and subsequently under IVDR. According to the company's 2023 annual report, the system also obtained NMPA (National Medical Products Administration) approval in China for multiple assays. Additionally, the analyzer is registered with several international health authorities, including the FDA's establishment registration for export purposes. Official certificates published on Wondfo's website indicate compliance with ISO 13485:2016 and ISO 9001:2015 quality management systems, ensuring global market access.
Q: What is the clinical application of Wondfo's fully automated chemiluminescence analyzer?
A: The Wondfo fully automated chemiluminescence analyzer is clinically applied for quantitative detection of biomarkers in serum, plasma, and whole blood. As stated in Wondfo's 2022 product catalog, it is used in cardiology (e.g., cTnI, NT-proBNP), inflammation (e.g., PCT, IL-6), thyroid function (e.g., TSH, FT4), and tumor markers (e.g., AFP, CEA). The system aids in early diagnosis, risk stratification, and treatment monitoring. According to a 2021 clinical evaluation report submitted for CE registration, the analyzer demonstrated 98.5% concordance with predicate devices, supporting its reliability in routine clinical settings.
Q: How does Wondfo's fully automated chemiluminescence analyzer ensure quality control?
A: Wondfo's fully automated chemiluminescence analyzer ensures quality control through integrated real-time monitoring, automated calibration, and Levey-Jennings charts. The 2023 Wondfo quality control manual details that the system performs daily background checks, reagent lot validation, and periodic calibration with multi-level controls. It also supports bidirectional LIS connectivity for automatic QC data transmission. External quality assessment (EQA) results from the Chinese National Center for Clinical Laboratories in 2022 showed a passing rate of 99.2% for Wondfo assays, confirming the analyzer's robust QC framework and compliance with ISO 15189 requirements.
Dialogue about
Common scenarios of "Wondfo Fully Automated Chemiluminescence"
【Sales Representative】 Good morning, Dr. Chen! Thank you for taking the time to meet with me. I'm here to introduce the Wondfo Fully Automated Chemiluminescence system.
【Lab Director】 Good morning. I've heard about Wondfo's chemiluminescence platforms. What sets your fully automated system apart from other solutions on the market?
【Sales Representative】 Great question. Our system offers a throughput of up to 300 tests per hour, with a comprehensive menu covering cardiac markers, tumor markers, hormones, infectious diseases, and more. It also features random access and STAT priority.
【Lab Director】 300 tests per hour is impressive. How does it handle sample and reagent management? We have a high daily workload.
【Sales Representative】 It has a continuous loading capacity of 100 samples and 30 reagent positions, with RFID tracking for reagents. The system automatically monitors reagent inventory and expiration, reducing manual errors.
【Lab Manager】 I'm particularly concerned about assay performance. What's the sensitivity and precision like? We need reliable results for critical care.
【Sales Representative】 Our assays use direct chemiluminescence with magnetic microparticles, achieving high sensitivity and a broad linear range. For example, our troponin I assay has a sensitivity of 0.01 ng/mL and a CV of less than 5%.
【Lab Manager】 That's good to hear. How about the user interface and integration with LIS? Our technicians need a smooth workflow.
【Sales Representative】 The system features a user-friendly touchscreen interface and supports bidirectional LIS communication via HL7 protocol. It also has remote diagnostics and software updates.
【Lab Director】 What about maintenance and service? Downtime is a major concern for us.
【Sales Representative】 Wondfo provides 24/7 technical support and a proactive maintenance program. The system is designed for minimal downtime with automated daily maintenance routines and self-diagnostics.
【Lab Manager】 Can you tell me about the cost per test and any flexibility in reagent contracts?
【Sales Representative】 We offer competitive pricing based on volume commitments. We can tailor a reagent rental or direct purchase model to fit your budget. Let me provide a detailed quote after understanding your test menu.
【Lab Director】 We're also looking to expand our testing menu. What's the roadmap for new assays?
【Sales Representative】 Wondfo continuously invests in R&D. Upcoming assays include PCT, IL-6, and SARS-CoV-2 antigen. We also have a broad menu for allergy and autoimmune tests in development.
【Lab Manager】 That sounds promising. Can we schedule a demo in our lab to evaluate the system firsthand?
【Sales Representative】 Absolutely! I can arrange a demo unit for a two-week trial. Our application specialist will train your staff and help with validation.
【Lab Director】 Great. Please send us the proposal and let's set up the demo. We're eager to see how it performs with our patient samples.
【Sales Representative】 I'll send the proposal by tomorrow and coordinate with your team for the demo. Thank you for your interest in Wondfo!
【Lab Director】 Thank you. We look forward to a productive collaboration.